New Applications in Healthcare

RNS Number : 2590M

Cambridge Cognition Holdings PLC

06 May 2015

 

Cambridge Cognition Holdings Plc

('Cambridge Cognition' or the 'Company')

New Applications in Healthcare for Cambridge Cognition Technology

Systems and methods for assessing cognitive function and symptoms of neurological and neuropsychiatric conditions

Cambridge Cognition Holdings plc, (AIM: COG), which specialises in computerised neuropsychological tests, announces that having commenced development activities for near-patient cognitive testing in its Healthcare business unit,  a new patent application has been filed covering 'systems and methods for assessing cognitive function and symptoms of neurological and neuropsychiatric conditions'. It has particular relevance for methods which use the results from wearable sensor(s) to identify a need to initiate cognitive testing.

The innovative nature of this programme and first patent application surrounds the use of wearable devices such as smartwatches which continuously monitor day-to-day activities of the user alongside biometric parameters such as pulse, movement, and voice and compares these measurements to a baseline that is normal for the individual. If the measured parameters deviate from the baseline this triggers cognitive testing of the individual through a mobile device such as a smartphone. The combination of bio-behavioural measures and results from cognitive tests are used to build up a picture of a person's mental function, identifying the very early signs of deterioration that could indicate Alzheimer's disease or other neurological conditions. This method of using wearable sensors to monitor normal cognitive function and provide an early indication of a deviation from that norm is highly innovative, fits well with the suite of cognitive function products that the Company has developed and is an area of significant growth potential for future product expansion.

The demand for early identification of the onset of dementia is increasing in order that early intervention can be instigated. As a result, the market for an early warning system is large and growing due to the frequency of dementia among the aging population and the cost per patient for care.

This patent will extend the Company's IP asset estate adding significantly to the technology value of the Company. Using novel technology to monitor cognitive function and identify early deterioration is in line with the Company's strategic vision of being a leader in cognitive assessment technology in healthcare.

Nick Kerton, Chief Executive Officer of Cambridge Cognition, said: "The novel technology around this patent builds nicely on our strategy going forward of providing technologies and products for early identification and intervention to maintain a healthy cognitive function. With the increasing impact of dementia on healthcare budgets, treating impairment early will have a significant positive impact on long term patient care for this very distressing disease."

Enquiries:

Cambridge Cognition Holdings plc	www.cambridgecognition.com
Nick Kerton, Chief Executive Officer	Tel: [phone]
Nick Walters, Chief Financial Officer
finnCap Ltd (Nomad and Broker)	Tel: [phone]
Geoff Nash/ Simon Hicks	(Corporate Finance)
Malar Velaigam	(Corporate Broking)
Walbrook PR Ltd	Tel: [phone] or [e-mail]
Paul McManus	Mob: [phone]
Lianne Cawthorne	Mob: [phone]

About Cambridge Cognition

Cambridge Cognition is a world leading provider of computerised cognitive assessment products.  The company's range of touch-screen CANTAB™ neuropsychological tests, highly validated over one thousand peer-reviewed publications, are used by both academic  scientists  in their research, and clinical researchers in the pharmaceutical industry, to maximise knowledge of cognitive function.  In addition, the company is committed to broadening the access to this technology and is developing clinical healthcare products under the Cantab mobile brand, to improve the monitoring, management and maintenance of cognitive health and wellbeing.  Using these assessments, clinicians can identify and stratify patients so that patient referrals are accurate and efficient, enabling health and social care providers to deliver more effective advice, treatments and care - leading to better outcomes for patients and their families. 

 

END

 

 

NRAEASSSELKSEFF